NHRA Joins WHO’s International Drug Monitoring Programme

Manama:The National Health Regulatory Authority (NHRA) has achieved full membership in the World Health Organization's (WHO) Programme for International Drug Monitoring (PIDM), marking a significant advancement in Bahrain's pharmacovigilance system. This development enhances Bahrain's role in international efforts to ensure medicine safety and protect public health.

According to Bahrain News Agency, Dr. Ahmed Mohammed Al Ansari, Chief Executive Officer of the NHRA, stated that this membership reflects Bahrain's technical and regulatory capabilities in pharmacovigilance. It also signifies the Kingdom's compliance with international requirements for participation in the global drug monitoring system. Dr. Al Ansari emphasized that this achievement is the result of ongoing national efforts to improve medicine control systems and enhance patient safety.

He further explained that the membership allows the national pharmacovigilance team to actively engage with an international network of national centers responsible for monitoring medicine safety. This participation includes contributing to global drug monitoring efforts through national reports and information, as well as benefiting from international data and expertise in identifying and assessing potential medicine-related risks. The NHRA plans to continue developing the national pharmacovigilance system, strengthening mechanisms for reporting suspected adverse drug reactions, and supporting the safe and rational use of medicines.

The WHO Programme for International Drug Monitoring is a global network that aims to enhance medicine safety by collecting, analyzing, and exchanging information on suspected adverse drug reactions among member countries. Full membership enables the NHRA to contribute to the global medicine safety database, VigiBase, managed by the Uppsala Monitoring Centre (UMC) on behalf of the WHO. This supports regulatory decisions based on scientific evidence and contributes to strengthening patient protection and public health.